ReviewWorld journal of urology2026
Vardenafil in the multidisciplinary management of erectile dysfunction: a narrative review on multidimensional outcomes and clinical integration.
Review in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundErectile dysfunction (ED) is a multifactorial condition that often indicates underlying systemic disorders. Among phosphodiesterase type 5 inhibitors (PDE5is), vardenafil has pharmacological properties that may provide advantages in certain clinical situations.
objectiveThis narrative review aims to synthesize current evidence on the pharmacological mechanisms, clinical efficacy, and future research directions of vardenafil in the multidisciplinary treatment of ED.
methodsA comprehensive literature search was conducted in PubMed, Web of Science, and Embase for studies published between January 2019 and March 2025, focusing on vardenafil’s pharmacology, clinical efficacy, and its integration with other therapeutic modalities (endocrine, psychological, lifestyle, cardiovascular). Relevant randomized controlled trials, cohort studies, and key mechanistic studies were reviewed. Due to the heterogeneity of the available evidence, a narrative synthesis was performed to summarize findings across different intervention domains.
resultsEvidence indicates that vardenafil demonstrates favorable short‑term efficacy across various etiologies of ED. Quantitative data from included studies (summarized in Table 1) support its efficacy as monotherapy and suggest synergistic benefits when combined with testosterone replacement therapy, psychological interventions, lifestyle modifications, and cardiovascular risk management. However, heterogeneity in sample sizes, follow‑up durations, and outcome measures limits the robustness of the current evidence.
conclusionsVardenafil represents a valuable treatment option within multidisciplinary management strategies for ED, particularly when its pharmacokinetic profile aligns with patient needs and preferences. High‑quality, long‑term randomized trials are necessary to determine optimal combination protocols, treatment duration, and long‑term safety, with particular emphasis on precision dosing and biomarker‑guided interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.